
OpinionSeptember 14, 2021
A Renaissance for Psychedelics Could Fill a Long-Standing Treatment Gap for Psychiatric Disorders
Psilocybin and MDMA represent a first wave of therapies that help patients by changing the way they view reality
Danielle Schlosser is a psychologist and senior vice president of clinical innovation at Compass Pathways, which is conducting clinical trials of psilocybin. In her prior role, she was in charge of vision and strategy for the behavioral health portfolio at Verily Life Sciences, an Alphabet company, and she remains on the faculty at the University of California, San Francisco.

A Renaissance for Psychedelics Could Fill a Long-Standing Treatment Gap for Psychiatric Disorders
Psilocybin and MDMA represent a first wave of therapies that help patients by changing the way they view reality